{
    "Trade/Device Name(s)": [
        "Tosoh Automated Glycohemoglobin Analyzer HLC-723G8"
    ],
    "Submitter Information": "Tosoh Bioscience, Inc.",
    "510(k) Number": "K200904",
    "Predicate Device Reference 510(k) Number(s)": [
        "K122472",
        "K142448"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ",
        "LCP"
    ],
    "Summary Letter Date": "September 14, 2021",
    "Summary Letter Received Date": "September 29, 2020",
    "Submission Date": "May 26, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.1373",
        "21 CFR 864.7470",
        "21 CFR 862.1150"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c test system",
        "Glycosylated hemoglobin assay",
        "Calibrator"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c (HbA1c)"
    ],
    "Specimen Type(s)": [
        "Venous Whole Blood"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "K3-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Tosoh Automated Glycohemoglobin Analyzer HLC-723G8"
    ],
    "Method(s)/Technology(ies)": [
        "Ion-exchange high-performance liquid chromatography (HPLC)",
        "Absorbance spectrophotometry"
    ],
    "Methodologies": [
        "HPLC separation and quantification"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 using ion-exchange HPLC for HbA1c quantitation in venous whole blood.",
    "Indications for Use Summary": "For in vitro diagnostic use to measure percent hemoglobin A1c (HbA1c) in venous whole blood as an aid in diagnosis and monitoring of diabetes and identifying at-risk patients.",
    "fda_folder": "Clinical Chemistry"
}